免疫功坊股份有限公司 IMMUNWORK
  • ( EN )
    • EN
    • 繁中
    CLOSE
  • About Us
    • Back
    • Overview
    • Founder
    • Executives
    • Scientific Advisors
    • Board of directors
  • Technologies
    • Back
    • Overview
    • T-ETMPharmaceuticals
    • Multi-arm linkers
    • Packed multi-arm linkers
    • Fatty acid bundles
  • Products
    • Back
    • Overview
    • TE-8105
    • TE-8214
    • TE-6168
    • TE-8035
  • News&Honors
  • Contact Us
  • ( English )
    • Back
    • English
    • 繁體中文
  • Copyright © 2017 MIRACLE

News&Honors

TE-8105 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
2021/04
06
【Reported by Taiwan CommonWealth Magazine】The name of novel drug, which get the largest authorization, comes from the birthday of "The father of antibodies in Taiwan"
2020/05
07
【Reported by Taiwan Global Bio Monthly】Immunwork Opening! A number of products will apply for IND from 2020
2019/09
17
Immunwork won the 2019 Outstanding Biotechnology Industry Award - Potential Benchmark Award!
2019/07
18
【Reported by Taiwan Science Moothly】Essence of new drug invention: breakthrough existing techniques to create greater medical value
2018/10
12
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Quick Menu

Immunwork, Inc., a wholly owned subsidiary of T-E Pharma Holding, a Cayman Island company.

Address: Room C520, Building C, No. 99, Lane 130, Sec. 1, Academia Rd,, Nangang District, Taipei City, Taiwan R.O.C. 115021
Email: bd@immunwork.com or service@immunwork.com
Phone: +886-2-2651-2268
Design assisted by WebTech Webpage design
go top